SG11201805621SA - Cancer vaccines - Google Patents

Cancer vaccines

Info

Publication number: SG11201805621SA
Authority: SG; Singapore
Prior art keywords: rule; international; immunogenic; polypeptides; san diego
Prior art date: 2016-01-19

Application number

SG11201805621SA

Other languages

English (en)

Inventor

Joseph John Binder

Helen Kim Cho

Paul Jason Cockle

Derek John Falconer

Siradanahalli Guru

Karin Ute Jooss

Marianne Marcela Andrea Martinic

Kenneth Nelson Wills

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-19

Filing date

2017-01-16

Publication date

2018-08-30

2017-01-16 Application filed by Pfizer filed Critical Pfizer

2018-08-30 Publication of SG11201805621SA publication Critical patent/SG11201805621SA/en

Links

229940022399 cancer vaccine Drugs 0.000 title abstract 2
238000009566 cancer vaccine Methods 0.000 title abstract 2
230000002163 immunogen Effects 0.000 abstract 7
102000004196 processed proteins & peptides Human genes 0.000 abstract 7
108090000765 processed proteins & peptides Proteins 0.000 abstract 7
229920001184 polypeptide Polymers 0.000 abstract 6
102000039446 nucleic acids Human genes 0.000 abstract 3
108020004707 nucleic acids Proteins 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
240000005020 Acaciella glauca Species 0.000 abstract 1
235000009899 Agrostemma githago Nutrition 0.000 abstract 1
101000576802 Homo sapiens Mesothelin Proteins 0.000 abstract 1
101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract 1
102100025096 Mesothelin Human genes 0.000 abstract 1
102100034256 Mucin-1 Human genes 0.000 abstract 1
240000001439 Opuntia Species 0.000 abstract 1
244000178320 Vaccaria pyramidata Species 0.000 abstract 1
239000011230 binding agent Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000008520 organization Effects 0.000 abstract 1
235000003499 redwood Nutrition 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4257—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)

SG11201805621SA 2016-01-19 2017-01-16 Cancer vaccines SG11201805621SA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662280636P	2016-01-19	2016-01-19
US201662419190P	2016-11-08	2016-11-08
PCT/IB2017/050229 WO2017125844A1 (fr)	2016-01-19	2017-01-16	Vaccins anticancéreux

Publications (1)

Publication Number	Publication Date
SG11201805621SA true SG11201805621SA (en)	2018-08-30

Family

ID=57960563

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201805621SA SG11201805621SA (en)	2016-01-19	2017-01-16	Cancer vaccines

Country Status (22)

Country	Link
US (3)	US10251944B2 (fr)
EP (2)	EP3733201A1 (fr)
JP (2)	JP6820935B2 (fr)
KR (2)	KR102158923B1 (fr)
CN (1)	CN108778321A (fr)
AU (1)	AU2017208848A1 (fr)
BR (1)	BR112018013967A2 (fr)
CA (1)	CA2954892A1 (fr)
CO (1)	CO2018007442A2 (fr)
DK (1)	DK3405212T3 (fr)
ES (1)	ES2811523T3 (fr)
HU (1)	HUE051722T2 (fr)
IL (2)	IL260321B (fr)
MX (1)	MX2018008797A (fr)
PH (1)	PH12018501532A1 (fr)
PL (1)	PL3405212T3 (fr)
PT (1)	PT3405212T (fr)
RU (2)	RU2020110148A (fr)
SG (1)	SG11201805621SA (fr)
SI (1)	SI3405212T1 (fr)
TW (3)	TW202111125A (fr)
WO (1)	WO2017125844A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE065176T2 (hu)	2016-06-02	2024-05-28	Ultimovacs Asa	Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében
US20200087390A1 (en)	2016-12-21	2020-03-19	Amgen Inc.	Anti-tnf alpha antibody formulations
WO2018204760A1 (fr) *	2017-05-05	2018-11-08	David Weiner	Associations d'anticorps anti-ctl4 et de vaccins, et leur utilisation en immunothérapie
KR20240046703A (ko) *	2021-06-09	2024-04-09	울티모박스 아베	접합체

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
US5288641A (en)	1984-06-04	1994-02-22	Arch Development Corporation	Herpes Simplex virus as a vector
CA1341423C (fr)	1984-10-31	2003-03-04	Paul A. Luciw	Proteines recombinantes de virus associes au syndrome d'adenopathie et/ou au syndrome d'immuno-deficience acquise
CA1288774C (fr)	1985-01-07	1991-09-10	Deborah A. Eppstein	Surfactants cationiques de type 1,2-dialkony-w- trialkylammonium
GB8508845D0 (en)	1985-04-04	1985-05-09	Hoffmann La Roche	Vaccinia dna
US5091309A (en)	1986-01-16	1992-02-25	Washington University	Sindbis virus vectors
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989001973A2 (fr)	1987-09-02	1989-03-09	Applied Biotechnology, Inc.	Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
US5591624A (en)	1988-03-21	1997-01-07	Chiron Viagene, Inc.	Retroviral packaging cell lines
US5716826A (en)	1988-03-21	1998-02-10	Chiron Viagene, Inc.	Recombinant retroviruses
US5217879A (en)	1989-01-12	1993-06-08	Washington University	Infectious Sindbis virus vectors
EP0737750B1 (fr)	1989-03-21	2003-05-14	Vical, Inc.	Expression de séquences polynucléotidiques exogènes chez un vertébré
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
WO1990014837A1 (fr)	1989-05-25	1990-12-13	Chiron Corporation	Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
US5279833A (en)	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
US5817491A (en)	1990-09-21	1998-10-06	The Regents Of The University Of California	VSV G pseusdotyped retroviral vectors
US5283185A (en)	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
AU671971B2 (en)	1991-11-29	1996-09-19	Chiron Corporation	Anti-cancer immunotherapeutic vector constructs
CA2138997C (fr)	1992-06-25	2003-06-03	Jean-Paul Prieels	Composition vaccinale qui contient des adjuvants
IL107366A (en)	1992-10-23	2003-03-12	Chugai Pharmaceutical Co Ltd	Genes coding for megakaryocyte potentiator
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5651981A (en)	1994-03-29	1997-07-29	Northwestern University	Cationic phospholipids for transfection
US5527928A (en)	1994-09-30	1996-06-18	Nantz; Michael H.	Cationic transport reagents
GB9513261D0 (en)	1995-06-29	1995-09-06	Smithkline Beecham Biolog	Vaccines
JP2000505787A (ja)	1996-01-05	2000-05-16	アメリカ合衆国	中皮抗原及びそれを標的化するための方法及びキット
US7375183B1 (en)	1996-01-05	2008-05-20	The United States Of America As Represented By The Department Of Health And Human Services	Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
AU734253B2 (en)	1996-03-20	2001-06-07	Sloan-Kettering Institute For Cancer Research	Conjugated mucin peptide vaccines
US6093809A (en)	1996-10-01	2000-07-25	University Technology Corporation	Telomerase
US6475789B1 (en)	1996-10-01	2002-11-05	University Technology Corporation	Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7585622B1 (en)	1996-10-01	2009-09-08	Geron Corporation	Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6261836B1 (en)	1996-10-01	2001-07-17	Geron Corporation	Telomerase
CN1254376A (zh)	1996-10-01	2000-05-24	杰龙公司	端粒酶逆转录酶
WO1998037919A1 (fr)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US7622549B2 (en)	1997-04-18	2009-11-24	Geron Corporation	Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en)	1997-04-18	2005-01-20	Geron Corporation	Vaccine containing the catalytic subunit of telomerase for treating cancer
AU7690898A (en)	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (fr)	1997-06-06	1998-12-10	Dynavax Technologies Corporation	Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation
GB9712347D0 (en)	1997-06-14	1997-08-13	Smithkline Beecham Biolog	Vaccine
AU1145699A (en)	1997-09-05	1999-03-22	Smithkline Beecham Biologicals (Sa)	Oil in water emulsions containing saponins
US6303114B1 (en)	1998-03-05	2001-10-16	The Medical College Of Ohio	IL-12 enhancement of immune responses to T-independent antigens
US6337200B1 (en)	1998-03-31	2002-01-08	Geron Corporation	Human telomerase catalytic subunit variants
WO1999052549A1 (fr)	1998-04-09	1999-10-21	Smithkline Beecham Biologicals S.A.	Compositions adjuvantes
US6962790B1 (en)	1998-09-23	2005-11-08	University Of Massachusetts Medical Center	Predictive assay for immune response
EE05627B1 (et)	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
JP2002539273A (ja)	1999-03-19	2002-11-19	スミスクラインビーチャムバイオロジカルズソシエテアノニム	ワクチン
CN1227030C (zh)	1999-04-19	2005-11-16	史密丝克莱恩比彻姆生物有限公司	包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6472028B1 (en)	1999-08-12	2002-10-29	Joseph Frazzitta	Method of producing a high gloss coating on a printed surface
CN102766210B (zh)	1999-08-24	2015-07-08	E.R.施贵宝&圣斯有限责任公司	人ctla-4抗体及其应用
CO5200838A1 (es)	1999-09-24	2002-09-27	Smithkline Beecham Corp	Vacunas
JP2003509473A (ja)	1999-09-24	2003-03-11	スミスクラインビーチャムバイオロジカルズソシエテアノニム	ワクチン
GB9930359D0 (en)	1999-12-22	2000-02-09	Glaxo Group Ltd	Novel polypeptides
WO2001060391A1 (fr)	2000-02-15	2001-08-23	Regents Of The University Of California	Vaccin universel et methode de traitement du cancer utilisant la transcriptase inverse de la telomerase
AU2001282290A1 (en)	2000-08-17	2002-03-04	University Of Wales College Of Medicine	Htert-immortalised cell lines, their preparation and use
US20040136963A1 (en)	2001-06-22	2004-07-15	The Trustees Of The University Of Pennsylvania	Simian adenovirus vectors and methods of use
AU2002363231A1 (en)	2001-10-29	2003-05-12	Baylor College Of Medicine	Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
TWI228718B (en)	2001-11-05	2005-03-01	Tdk Corp	Manufacturing method and device of mold plate for information medium
DE10162480A1 (de)	2001-12-19	2003-08-07	Ingmar Hoerr	Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
GB0212046D0 (en) *	2002-05-24	2002-07-03	Glaxo Group Ltd	Vaccines
US9200036B2 (en)	2002-07-12	2015-12-01	The Johns Hopkins University	Mesothelin vaccines and model systems
AU2003259109A1 (en)	2002-07-12	2004-02-02	The Johns Hopkins University	Mesothelin vaccines and model systems
CN1315536C (zh) *	2002-09-13	2007-05-16	李进	肿瘤抗原疫苗及其制备方法和疫苗组合物
SI2163260T1 (sl)	2004-01-23	2017-07-31	Msd Italia S.R.L.	Nosilci šimpanzjih adenovirusnih cepiv
DE102004035227A1 (de)	2004-07-21	2006-02-16	Curevac Gmbh	mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
JP4088328B2 (ja) *	2004-12-28	2008-05-21	第一化学薬品株式会社	抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
EP1748067A1 (fr)	2005-07-29	2007-01-31	Institut Pasteur	Polynucleotides codant pour des épitopes de la hTERT restreints au CMH de classe I, analogues et polyépitopes
JP2009523817A (ja)	2006-01-19	2009-06-25	ザリージェンツオブザユニバーシティオブカリフォルニア	ヒトテロメラーゼ逆転写酵素ペプチド
ATE534661T1 (de) *	2006-10-12	2011-12-15	Angeletti P Ist Richerche Bio	Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
EP1994942A1 (fr)	2007-05-25	2008-11-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions pharmaceutiques comprenant de la télomérase et leurs utilisations
WO2009025871A1 (fr)	2007-08-23	2009-02-26	University Of Medicine And Dentistry Of Nj	Variant de transcriptase inverse de télomérase
WO2009046738A1 (fr) *	2007-10-09	2009-04-16	Curevac Gmbh	Composition pour traiter le cancer du poumon, notamment les cancers du poumon non à petites cellules (nsclc)
ES2524266T3 (es)	2008-07-08	2014-12-04	Incyte Corporation	1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
CA2749325C (fr)	2009-02-02	2021-03-30	Okairos Ag	Sequences d'acide amine et d'acide nucleique d'adenovirus simien, vecteurs les contenant, et utilisations afferentes
CN101920009B (zh)	2010-03-06	2012-08-08	河北医科大学	一种用于预防和治疗肿瘤的疫苗
US20140335050A1 (en) *	2011-05-27	2014-11-13	The General Hospital Corporation	Methods, compositions, and kits for the treatment of cancer
US20130028915A1 (en)	2011-07-27	2013-01-31	Baylor Research Institute	Dendritic cell (dc)-vaccine therapy for pancreatic cancer
US8523590B2 (en) *	2011-07-29	2013-09-03	General Electric Company	Cable system and methods of assembling a cable system
RU2642300C2 (ru) *	2011-08-17	2018-01-24	Глоубиммьюн, Инк.	Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
RU2737765C2 (ru) *	2012-05-04	2020-12-02	Пфайзер Инк.	Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
US10184216B2 (en) *	2012-07-18	2019-01-22	Thomas Urbanek	Advantageous detectable warning area and methods of forming the same
US20140234351A1 (en) *	2013-02-14	2014-08-21	Immunocellular Therapeutics, Ltd.	Cancer vaccines and vaccination methods
WO2014144885A2 (fr)	2013-03-15	2014-09-18	The Trustees Of The University Of Pennsylvania	Vaccins anticancéreux et méthodes de traitement les utilisant
HUE043042T2 (hu)	2013-11-01	2019-07-29	Pfizer	Vektorok prosztatához kapcsolódó antigének expressziójára
TN2016000501A1 (en)	2014-05-15	2018-04-04	Iteos Therapeutics	Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors.

2017
- 2017-01-16 ES ES17702951T patent/ES2811523T3/es active Active
- 2017-01-16 TW TW109135756A patent/TW202111125A/zh unknown
- 2017-01-16 SG SG11201805621SA patent/SG11201805621SA/en unknown
- 2017-01-16 KR KR1020187023390A patent/KR102158923B1/ko not_active Expired - Fee Related
- 2017-01-16 DK DK17702951.9T patent/DK3405212T3/da active
- 2017-01-16 AU AU2017208848A patent/AU2017208848A1/en not_active Abandoned
- 2017-01-16 RU RU2020110148A patent/RU2020110148A/ru unknown
- 2017-01-16 PT PT177029519T patent/PT3405212T/pt unknown
- 2017-01-16 RU RU2018126487A patent/RU2718663C2/ru active
- 2017-01-16 EP EP20175571.7A patent/EP3733201A1/fr not_active Withdrawn
- 2017-01-16 PL PL17702951T patent/PL3405212T3/pl unknown
- 2017-01-16 WO PCT/IB2017/050229 patent/WO2017125844A1/fr not_active Ceased
- 2017-01-16 SI SI201730373T patent/SI3405212T1/sl unknown
- 2017-01-16 MX MX2018008797A patent/MX2018008797A/es unknown
- 2017-01-16 HU HUE17702951A patent/HUE051722T2/hu unknown
- 2017-01-16 BR BR112018013967A patent/BR112018013967A2/pt not_active IP Right Cessation
- 2017-01-16 TW TW106101436A patent/TWI654302B/zh not_active IP Right Cessation
- 2017-01-16 EP EP17702951.9A patent/EP3405212B1/fr active Active
- 2017-01-16 CA CA2954892A patent/CA2954892A1/fr active Pending
- 2017-01-16 JP JP2018537450A patent/JP6820935B2/ja not_active Expired - Fee Related
- 2017-01-16 KR KR1020207026620A patent/KR20200109395A/ko not_active Ceased
- 2017-01-16 TW TW108100405A patent/TWI709647B/zh not_active IP Right Cessation
- 2017-01-16 CN CN201780018354.0A patent/CN108778321A/zh active Pending
- 2017-01-17 US US15/407,890 patent/US10251944B2/en not_active Expired - Fee Related
2018
- 2018-06-27 IL IL260321A patent/IL260321B/en active IP Right Grant
- 2018-07-16 CO CONC2018/0007442A patent/CO2018007442A2/es unknown
- 2018-07-18 PH PH12018501532A patent/PH12018501532A1/en unknown
2019
- 2019-01-18 US US16/252,239 patent/US11058753B2/en not_active Expired - Fee Related
2020
- 2020-10-01 IL IL277752A patent/IL277752A/en unknown
2021
- 2021-01-05 JP JP2021000428A patent/JP2021061851A/ja active Pending
- 2021-05-13 US US17/319,395 patent/US20220323558A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN108778321A (zh)	2018-11-09
TW201738377A (zh)	2017-11-01
PT3405212T (pt)	2020-08-25
EP3733201A1 (fr)	2020-11-04
EP3405212B1 (fr)	2020-07-08
ES2811523T3 (es)	2021-03-12
TWI709647B (zh)	2020-11-11
US20190142918A1 (en)	2019-05-16
RU2018126487A3 (fr)	2020-02-20
EP3405212A1 (fr)	2018-11-28
PL3405212T3 (pl)	2020-11-16
WO2017125844A1 (fr)	2017-07-27
SI3405212T1 (sl)	2020-09-30
IL260321A (en)	2018-08-30
BR112018013967A2 (pt)	2019-02-05
JP2019505210A (ja)	2019-02-28
AU2017208848A1 (en)	2018-07-12
MX2018008797A (es)	2018-11-29
KR102158923B1 (ko)	2020-09-23
TWI654302B (zh)	2019-03-21
KR20180101537A (ko)	2018-09-12
IL260321B (en)	2020-10-29
TW202111125A (zh)	2021-03-16
RU2718663C2 (ru)	2020-04-13
CA2954892A1 (fr)	2017-07-19
RU2018126487A (ru)	2020-02-20
CO2018007442A2 (es)	2018-07-31
PH12018501532A1 (en)	2019-05-15
TW201932598A (zh)	2019-08-16
JP6820935B2 (ja)	2021-01-27
KR20200109395A (ko)	2020-09-22
US10251944B2 (en)	2019-04-09
JP2021061851A (ja)	2021-04-22
US11058753B2 (en)	2021-07-13
IL277752A (en)	2020-11-30
DK3405212T3 (da)	2020-08-24
HUE051722T2 (hu)	2021-03-29
US20220323558A1 (en)	2022-10-13
RU2020110148A (ru)	2020-09-18
US20170202938A1 (en)	2017-07-20

Publication	Publication Date	Title
SG11201811232XA (en)	2019-01-30	Treatment of amd using aav2 variant with aflibercept
SG11201810485SA (en)	2018-12-28	Substituted carbonucleoside derivatives useful as anticancer agents
SG11201810023QA (en)	2018-12-28	Anti-tim-3 antibodies and methods of use thereof
SG11201811230RA (en)	2019-01-30	Compositions and methods for reducing ocular neovascularization
SG11201906392WA (en)	2019-08-27	Nucleoside-modified rna for inducing an immune response against zika virus
SG11201909955XA (en)	2019-11-28	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201804704PA (en)	2018-07-30	Compositions and methods for decreasing tau expression
SG11201807538PA (en)	2018-09-27	Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201811432WA (en)	2019-03-28	Rna for cancer therapy
SG11201808622SA (en)	2018-10-30	Chimeric receptors to flt3 and methods of use thereof
SG11201805217XA (en)	2018-07-30	Compositions and methods for the treatment of hemoglobinopathies
SG11201806863WA (en)	2018-09-27	Tetracyclic pyridone compounds as antivirals
SG11201908512YA (en)	2019-10-30	Somatostatin modulators and uses thereof
SG11201901206SA (en)	2019-04-29	Trimer stabilizing hiv envelope protein mutations
SG11201903857UA (en)	2019-05-30	Antibodies to pd-1 and uses thereof
SG11201810591VA (en)	2018-12-28	Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
SG11201808751SA (en)	2018-11-29	T cell receptors
SG11201407875UA (en)	2014-12-30	Compostions and methods for cancer immunotherapy
SG11202000312UA (en)	2020-02-27	Encapsulated polynucleotides and methods of use
SG11201810522UA (en)	2018-12-28	Anti-cd40 antibodies and their uses
SG11201909011PA (en)	2019-10-30	Niraparib compositions
SG11201908326YA (en)	2019-10-30	Methods of treating neurodegenerative diseases
SG11201804951SA (en)	2018-07-30	Use of tryptophan derivatives for protein formulations
SG11201901228QA (en)	2019-03-28	Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201809531SA (en)	2018-11-29	BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF